NEW YORK (GenomeWeb) – CombiMatrix today reported that its second quarter revenues rose 29 percent year over year, driven by 60 percent growth in prenatal microarray testing volumes.

For the three months ended June 30, the Irvine, Calif.-based molecular diagnostics company saw revenues climb to $1.9 million from $1.5 million in the second quarter of 2013. Its revenues were in line with the consensus Wall Street estimate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.